Impact of regulatory interventions to restrict the combined use of renin–angiotensin system blockers: A Danish nationwide drug utilisation study-Reference-Cited by-同舟云学术

Impact of regulatory interventions to restrict the combined use of renin–angiotensin system blockers: A Danish nationwide drug utilisation study

Published:2021-10-08 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Sindahl Per¹²³^ORCID,Ofori‐Asenso Richard³,Hallgreen Christine Erikstrup³,Kemp Kaare¹,Gardarsdottir Helga²⁴^ORCID,De Bruin Marie Louise²³⁵

Affiliation:

1. Division of Pharmacovigilance and Medical Devices Danish Medicines Agency Copenhagen Denmark

2. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science Utrecht University Utrecht The Netherlands

3. Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

4. Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics University Medical Center Utrecht Utrecht the Netherlands

5. Department of Pharmaceutical Sciences, School of Health Sciences University of Iceland Reykjavik Iceland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15080

Reference21 articles.

1. Measuring the impact of risk communications: Robust analytical approaches are key

2. European Medicines Agency.Renin‐angiotensin‐system (RAS)‐acting agents. European Medicines Agency. Published September 17 2018. Accessed August 20 2020.https://www.ema.europa.eu/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents

3. Overview of the renin‐angiotensin system ‐ UpToDate. Accessed September 1 2020.https://www.uptodate.com/contents/overview-of-the-renin-angiotensin-system?search=renin%20angiotensin%20%20agents&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

4. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

5. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy